Aprea Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Aprea Therapeutics, Inc. (APRE) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $182.04 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-03-26
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $61.25K, a 7.63% decline year-over-year.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $59.97K, a 5.02% increase year-over-year.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was $60.83K, a 16.01% decline year-over-year.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $182.04K, a 29.67% decline from fiscal 2021.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $258.85K, a 28.92% increase from fiscal 2020.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $200.78K, a 26.17% increase from fiscal 2019.
- Aprea Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2019 was $159.13K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $61.25K derived: sum of 2 quarters · filed 2024-03-26 | $121.22K derived: sum of 3 quarters · filed 2024-03-26 | $182.04K 10-K · filed 2024-03-26 |
| 2022-09-30 | $61.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $121.22K derived: sum of 2 quarters · filed 2023-11-09 | $182.04K 10-Q · filed 2023-11-09 | $245.06K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-06-30 | $59.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $120.80K 10-Q · filed 2023-08-10 | $183.82K derived: sum of 3 quarters · filed 2024-03-26 | $250.13K derived: sum of 4 quarters · filed 2024-03-26 |
| 2022-03-31 | $60.83K 10-Q · filed 2023-05-15 | $123.85K derived: sum of 2 quarters · filed 2024-03-26 | $190.16K derived: sum of 3 quarters · filed 2024-03-26 | $247.26K derived: sum of 4 quarters · filed 2024-03-26 |
| 2021-12-31 | $63.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $129.33K derived: sum of 2 quarters · filed 2024-03-26 | $186.43K derived: sum of 3 quarters · filed 2024-03-26 | $258.85K 10-K · filed 2024-03-26 |
| 2021-09-30 | $66.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $123.41K derived: sum of 2 quarters · filed 2022-11-09 | $195.82K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $57.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $129.52K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $72.42K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $200.78K 10-K · filed 2023-03-30 | |||
| 2019-12-31 | $159.13K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |